Algés, Oeiras Mon to Fri · 09:00 to 13:00 and 14:00 to 19:00 · Sat · 09:00 to 14:00
WhatsApp Book a consultation
  1. Home
  2. Aesthetic gynaecology
  3. Vagina that closes up during penetration
  4. Botulinum toxin in vaginismus

Botulinum toxin in vaginismus: what is known (off-label use)

A second-line option for vaginismus that has not improved with the usual treatment, used outside the approved indications. See what is known and the limits.

Luxmed TeamAuthor
Dr Michelle CampagnoliClinical review · OM no. 69467
7 min read
Foto de capa · a do cartão do blog1200 × 800 px (3:2)
Quando existir, entra aqui e também no cartão da página do blog.
In this article
  1. In short
  2. How it works
  3. Why we speak of “use outside the approved indications”
  4. What the evidence says
  5. Who it may make sense for
  6. How it is done
  7. Possible adverse effects
  8. What the toxin does not do
  9. When to see a doctor
  10. At Luxmed Clinic
  11. Frequently asked questions

Botulinum toxin is known mainly for its use in facial aesthetics, but it has also been used for decades in neurology and urology to relax muscles in spasm. In recent years, it has been studied in vaginismus, especially in women who have not improved with the usual treatment.

It is an option that attracts considerable interest and some unrealistic expectations. In this article, we explain how it works, what the studies show, who might benefit and what its limitations are. It is important to emphasise from the outset that botulinum toxin is not approved for vaginismus in Portugal or the European Union. Its use for this condition is off-label.

In 30 seconds

Three ideas to remember.

1Off-label useBotulinum toxin temporarily relaxes the muscles into which it is injected. Its use for vaginismus is off-label, and the evidence comes mainly from case series without a control group.
2Second lineIt is generally reserved for cases that have not improved with physiotherapy, dilators and psychological support.
3It does not replace treatmentIt should always be combined with physiotherapy, dilators and psychological support.
Imagem opcional · abertura1200 × 800 px
Fica por baixo do resumo, se existir uma segunda foto.

How it works

Botulinum toxin blocks the release of acetylcholine, the substance nerves use to tell muscles to contract. When injected into a muscle, it reduces the muscle’s ability to contract for a few weeks to several months. The effect then wears off gradually as the nerves form new nerve endings.

In vaginismus, the idea is to temporarily reduce the involuntary contraction of the muscles at the entrance of the vagina. With less contraction, the woman can progress more easily with dilators and gradual exposure. The aim is not to “paralyse” permanently, but to open a window in which the body learns that penetration can happen without pain.

Why we speak of “use outside the approved indications”

Each medicine is approved for specific indications on the basis of clinical trials submitted to the regulatory authorities. Botulinum toxin is approved, for example, for some types of spasticity, dystonia, overactive bladder and chronic migraine, as well as for cosmetic indications. Vaginismus is not one of them.

Using a medicine outside the approved indications is legal and is sometimes the best option available. But it means that the evidence is less robust, that the decision is made by the doctor together with the patient, and that the patient must be clearly informed about this, in writing.

What the evidence says

  • Case series. Most of the data come from groups of women who were treated and followed up, without a comparison group. In these series, a high proportion of women with vaginismus who had not responded to other treatments were able to have penetrative sex after the injection, combined with dilators and follow-up (Ghazizadeh and Nikzad, 2004, Bertolasi et al., 2009). The largest series, with more than 200 women, comes from a single centre that also dilates the vagina under anaesthesia (Pacik and Geletta, 2017).
  • Randomised trials. There are few. In vestibulodynia, a closely related condition, two placebo-controlled trials found no clear benefit of the toxin in reducing pain (Petersen et al., 2009, Haraldson et al., 2020).
  • Systematic reviews. They conclude that the evidence is of low quality and that controlled trials are needed before its routine use can be recommended (Maseroli et al., 2018, Melnik et al., 2012).

Taken together, the results of the case series are encouraging, but they do not make it possible to distinguish the effect of the toxin from those of intensive follow-up, dilators and expectations. It is a plausible option, but has not yet been proven effective.

Who it may make sense for

Botulinum toxin is not a first-line treatment. It can be discussed when:

  • the diagnosis of vaginismus is confirmed and other causes of pain have been excluded;
  • the woman has consistently completed an appropriate programme of pelvic physiotherapy, dilators and psychological or sexological support, without sufficient progress;
  • the muscle contraction is intense and prevents progress with dilators;
  • the woman is informed about the off-label nature, the limited evidence and the risks, and wishes to proceed.

It is not indicated during pregnancy or breastfeeding, in people with certain neuromuscular disorders (such as myasthenia gravis), if there is an infection at the injection site, or in those taking certain medicines that interact with the toxin, such as some aminoglycoside antibiotics.

How it is done

Protocols vary between centres. In general:

  1. the injection is given by an experienced doctor, in some cases under sedation or anaesthesia, to avoid discomfort and anxiety;
  2. the toxin is injected at several points in the muscles around the vaginal opening, sometimes with electromyographic guidance;
  3. the effect starts within a few days and reaches its maximum in about two weeks;
  4. an intensive programme of dilators and follow-up then follows, which is an essential part of the treatment;
  5. the effect lasts a few months. If the woman progresses during that period, many do not need to repeat it.

Possible adverse effects

At the doses used, adverse effects are usually mild and temporary:

  • pain or bruising at the site;
  • temporary leakage of urine or difficulty controlling wind if the toxin affects neighbouring muscles;
  • a feeling of pelvic weakness;
  • rarely, effects at a distance, such as generalised muscle weakness, blurred vision or difficulty swallowing, which require immediate medical assessment.

What the toxin does not do

  • It does not treat fear. The component of anxiety and anticipation of pain still needs psychological work and gradual exposure.
  • It does not replace dilators. Without the exposure programme, the effect tends to be lost when the toxin stops acting.
  • It does not resolve other causes of pain, such as vestibulodynia, atrophy or diseases of the vulvar skin.
  • It is not an aesthetic treatment nor a “rejuvenating” one.

When to see a doctor

If you have vaginismus and have not improved with the usual treatment, talk to your doctor about second-line options, including botulinum toxin, and about the pros and cons in your case. If you have not yet completed a structured programme of physiotherapy and dilators, that remains the first step.

Seek help immediately if, after the injection

Tick what applies to you.

In these situations, call 112. If in doubt, call the SNS 24 line (808 24 24 24).

At Luxmed Clinic

At Luxmed Clinic, we assess each case of vaginismus with time and always start with the treatments with the most evidence. When these are not enough, we discuss second-line options with you, explaining clearly what is known, what is not known and what use outside the approved indications involves, so that you can decide in an informed way.

Talk to us

The assessment is a conversation, with no obligation. Tell us what concerns you and our team will reply.

info@luxmed.pt

This article is for information only and does not replace a medical assessment. Results vary from person to person.

Frequently asked questions

Does botulinum toxin cure vaginismus?

There is not enough evidence to say so. It may help some women progress with treatment, always combined with dilators and psychological support.

Is it the same substance used for wrinkles?

The active ingredient belongs to the same family, but the doses, injection sites and purpose are different.

Does it hurt?

An injection in the vulvar area can be uncomfortable, especially for someone with vaginismus. That is why some centres give it under sedation or anaesthesia.

How long does the effect last?

Generally, a few months. The aim is to use that period to progress with the dilators, so that the result is maintained afterwards.

Can it be used as a first-line treatment?

It is not recommended. Most women improve with physiotherapy, dilators and therapy, which have more evidence and fewer risks.

Scientific references 7
  1. Pacik PT, Geletta S. Vaginismus treatment: clinical trials follow up 241 patients. Sex Med. 2017;5(2):e114-e123. doi:10.1016/j.esxm.2017.02.002 Artigo
  2. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104(5 Pt 1):922-925. doi:10.1097/01.AOG.0000141441.41178.6b Artigo
  3. Bertolasi L, Frasson E, Cappelletti JY, et al. Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol. 2009;114(5):1008-1016. doi:10.1097/AOG.0b013e3181bb0dbb Artigo
  4. Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A, a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6(9):2523-2537. doi:10.1111/j.1743-6109.2009.01378.x Artigo
  5. Haraldson P, Mühlrad H, Heddini U, Nilsson K, Bohm-Starke N. Botulinum toxin A as a treatment for provoked vestibulodynia: a randomized controlled trial. Obstet Gynecol. 2020;136(3):524-532. doi:10.1097/AOG.0000000000004008 Artigo
  6. Maseroli E, Scavello I, Rastrelli G, et al. Outcome of medical and psychosexual interventions for vaginismus: a systematic review and meta-analysis. J Sex Med. 2018;15(12):1752-1764. doi:10.1016/j.jsxm.2018.10.003 Revisão sistemática
  7. Melnik T, Hawton K, McGuire H. Interventions for vaginismus. Cochrane Database Syst Rev. 2012;(12):CD001760. doi:10.1002/14651858.CD001760.pub2 Revisão Cochrane
Written byLuxmed Team
Clinical reviewDr Michelle CampagnoliOM no. 69467 · Doctor with Competence in Aesthetic Medicine.View profile →

Editing and development: Rúben Brito · Operial Development

Book a consultation

Book your consultation

Choose how you prefer to get in touch. We will arrange the assessment consultation with Dr Michelle Campagnoli.

Booking through the websiteAssessment consultationTalk to our assistant on WhatsApp and ask for the current price of the assessment.

New Life Miraflores, Algés · Office Center, R. Santa Teresa do Menino Jesus n.º 6, 9.º C, 1495-048

Your details are used only for this contact. Any treatment depends on a prior medical assessment.

Request an appointmentIt takes less than a minute.
Speciality
You do not need to go into detail. The doctor will talk to you during the consultation.
Request received. Our team will contact you as soon as possible.
CallAssistantAvailableBook